LARGE B-CELL LYMPHOMA

This early-stage study is testing whether it's safe to give patients a second dose of CAR-T cell therapy if their aggressive lymphoma returns after the first treatment. Researchers will enroll about 20 adults whose cancer came back despite receiving standard CAR-T therapy. The ma…

This study is testing whether combining two drugs, epcoritamab and loncastuximab tesirine, is safe and effective for adults with large B-cell lymphoma that has returned or stopped responding to prior treatments. The main goal is to see if the combination can reduce or eliminate c…

This study is testing whether adding experimental drugs after CAR-T cell therapy can help control lymphoma that has returned or hasn't responded to previous treatments. The research involves 42 adults with large B-cell lymphoma who have already received CAR-T therapy. Participant…

This early-stage study is testing whether a drug called NT-I7 can make CAR-T cell therapy work better for people with large B-cell lymphoma that has come back or hasn't responded to treatment. Researchers want to see if giving NT-I7 after standard CAR-T therapy is safe and if it …

This trial is testing a new, experimental CAR-T cell therapy called WZTL-002 for people with aggressive large B-cell lymphoma that has returned or not responded to standard chemotherapy. The main goals are to see how well the therapy works to eliminate the cancer and to understan…

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is testing a two-step treatment for patients with large B-cell lymphoma that has come back or hasn't responded to other treatments. First, patients receive targeted radiation to all visible cancer sites to shrink large tumors. Then, they receive a personalized immune c…

This study is testing if a new treatment plan is better for older or frail adults with a type of blood cancer called large B-cell lymphoma. It compares a shorter course of standard chemotherapy followed by a new drug (AZD0486) against a longer course of standard chemotherapy alon…

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This study is testing whether adding a new drug called epcoritamab to a standard, gentler chemotherapy combination can help control a fast-growing type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is specifically for older adults or those with heart problems w…

This study is testing whether a combination of two drugs (tafasitamab and lenalidomide) can help people with large B-cell lymphoma who still have cancer after receiving CAR-T cell therapy. The research aims to see if this treatment is safe and effective at eliminating or reducing…

This program provides access to a specialized immune cell therapy (CAR-T) for patients with certain lymphomas when their manufactured treatment doesn't meet regular commercial standards but still meets safety requirements for clinical use. It's designed for patients who cannot un…

This study is testing whether a new type of 'off-the-shelf' CAR T-cell therapy can help prevent cancer from coming back in adults with large B-cell lymphoma. Participants who have finished their first round of treatment and have only tiny amounts of cancer cells left are randomly…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing whether a drug called loncastuximab tesirine can help control large B-cell lymphoma in patients whose cancer has come back or didn't fully respond to previous treatments. The research focuses on people who showed a partial response after receiving CAR T-cell…

This study is testing a new combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) for patients with an aggressive type of lymphoma that has come back or not responded to prior treatment and has a specific genetic change called TP53. The main goal is to see i…

This early-stage study is testing a new drug called AZD0486, both alone and combined with other cancer treatments, for people with advanced B-cell blood cancers that have returned or stopped responding to prior therapies. It aims to find a safe dose and see if the drug can shrink…

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This study looks back at the medical records of about 250 patients in France who have already received a lymphoma drug called Glofitamab. The goal is to understand how well the treatment worked and how safe it was in everyday medical practice, especially for patients whose cancer…

This small, early study is checking if a ketone supplement drink is safe and tolerable for people with a type of lymphoma who are getting standard CAR-T cell therapy. Researchers want to see if taking the supplement changes the mix of bacteria in the gut or the types of cells in …

This early-stage study is testing whether collecting a patient's own blood-forming stem cells and giving them back alongside CAR-T therapy is safe and feasible for people with aggressive blood cancers that have come back or not responded to other treatments. The main goals are to…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This early-stage study is testing the safety and initial effectiveness of a new drug called UB-VV400, both alone and combined with an existing drug called rapamycin. It is for adults with aggressive B-cell lymphoma that has come back or stopped responding to other treatments, inc…

This study is testing a new training program called Hematolo-GIST, designed to help lymphoma doctors communicate more effectively with their patients. It involves 48 doctors and their patients with a specific type of aggressive lymphoma. The main goal is to see if the training is…

This study aims to discover what factors predict whether a powerful cell therapy (CAR-T) will work for patients with large B-cell lymphoma that has returned or not responded to other treatments. Researchers will follow 80 patients receiving standard CAR-T therapy to analyze their…